Clinical Use of Cardiac Magnetic Resonance in Systemic Heart Disease

Sophie Mavrogeni, George Markousis-Mavrogenis and Genovefa Kolovou

Onassis Cardiac Surgery Center, Athens, Greece

Abstract

A systemic disease is one that affects a number of organs and tissues, or the body as a whole. Systemic diseases include endocrine, metabolic, nutritional, multisystem (rheumatic) and HIV disease. Cardiovascular involvement is a common and underestimated problem in systemic diseases, and may present with disease associated cardiac involvement at diagnosis or later in the course of the systemic disease. The cardiac involvement in these diseases is usually silent or oligo-symptomatic and includes different pathophysiological mechanisms such as, myocardial inflammation, infarction, diffuse, subendocardial vasculitis, valvular disease and different patterns of fibrosis. Furthermore, acuity of heart involvement may be underestimated due to non-specific cardiac signs, and finally, most of patients are female and unable to exercise, due to arthritis or muscular discomfort/weakness or may have limited acoustic window, due to increased breast size. Cardiovascular magnetic resonance (CMR), due to its ability to reliably assess cardiac anatomy, function, inflammation, stress perfusion-fibrosis, aortic distensibility, and iron and fat deposition, constitutes an excellent tool for early diagnosis of heart involvement, risk stratification, treatment evaluation and long-term follow-up of patients with cardiac disease due to systemic diseases.

Keywords

Rheumatic diseases, metabolic diseases, iron overload, cardiovascular magnetic resonance imaging

Disclosure: The authors have no conflicts of interest to declare.

Received: 25 March 2014 **Accepted:** 28 June 2014 **Citation:** *European Cardiology Review*, 2014;9(1):21–7

Correspondence: Sophie Mavrogeni, Onassis Cardiac Surgery Center, 50 Esperou Street, 175-61, P. Faliro, Athens, Greece. E: soma13@otenet.gr

Systemic means ‘pertaining to or affecting the whole body’ as opposed to a localised condition. A systemic disease is one that affects a number of organs and tissues, or the body as a whole. Systemic diseases, according to WHO classification,¹ and cardiac diseases that developed during their course, are listed in *Table 1*.

Thyroid diseases, pheochromocytoma and growth hormone excess may contribute to usually reversible dilated cardiomyopathy.² Hereditary haemochromatosis is an inherited disorder of iron metabolism; if left untreated, leads to tissue iron overload, iron cardiomyopathy and heart failure. Cardiac amyloidosis is the result of amyloid deposition in the heart, formed from breakdown of normal or abnormal proteins that lead to increased heart stiffness, restrictive cardiomyopathy and heart failure. Finally, nutritional disturbances and metabolic diseases, such as Kwashiorkor, Beri-beri, obesity and diabetes mellitus may also lead to dilated cardiomyopathy and heart failure.³

Cardiovascular involvement is a common and underestimated problem in multisystem (rheumatic) diseases and may present with disease associated cardiac involvement at diagnosis or later in the course of the systemic disease. It usually has a silent or oligo-symptomatic cardiac presentation and includes different pathophysiological mechanisms such as, myocardial inflammation, infarction, diffuse, subendocardial vasculitis, valvular disease and different patterns of fibrosis; furthermore, acuity of heart involvement may be underestimated due to non-specific cardiac signs, and most of patients are female and unable to exercise due to arthritis or muscular discomfort/weakness or may have limited acoustic window due to increased breast size.⁴

Finally, HIV-infected patients have an increased risk of coronary artery disease (CAD) and myocardial inflammation frequently leading to heart failure. This is due to different factors including: conventional risk factors, HIV-specific processes driving inflammation, coagulation and endothelial dysfunction.⁵

Cardiovascular magnetic resonance (CMR) through its ability to reliably assess cardiac anatomy, function, inflammation, stress perfusion-fibrosis, aortic distensibility, and iron and fat deposition, constitutes an excellent tool for early diagnosis of cardiovascular involvement, risk stratification, treatment evaluation and long-term follow-up of patients with cardiovascular disease due to systemic diseases.

Cardiovascular Magnetic Resonance Applications of Special Interest for Cardiovascular Evaluation in Systemic Diseases Measurement of Volumes – Ejection Fraction

CMR measures ventricular volumes and ejection fraction non-invasively and without contrast agent.⁶ Due to its high reproducibility, it is ideal for serial follow-up of ventricular volumes, mass and function; compared with echocardiography, which is an operator-dependent technique, with the limitations of acoustic window, CMR is operator-independent and has high reproducibility.⁷

The majority of CMR data regarding volumes and mass in systemic disease are referred to patients with metabolic diseases and mainly to diabetes mellitus. In patients with type 1 diabetes mellitus (T1DM), it was documented by CMR that in addition to traditional

Table 1: Systemic Diseases, According to WHO Classification, and Cardiac Diseases that may be Developed During their Course

Endocrine and Metabolic Diseases	Nutrition	Multisystem (Rheumatic) Diseases	HIV Infection
Diabetes mellitus Coronary artery disease Diabetic cardiomyopathy Heart failure	Malnutrition Low output heart failure Arrhythmia Sudden death	Rheumatoid arthritis and other seronegative arthritis Myocarditis Dilated Cardiomyopathy Coronary artery disease Valvular disease Heart failure	Myocarditis Cardiomyopathy Coronary artery disease Sudden death
Hyperthyroidism Supraventricular and ventricular tachycardia Dilated cardiomyopathy Heart failure	Thiamine deficiency Heart failure	Systemic lupus erythematosus Myocarditis Dilated cardiomyopathy Coronary artery disease Valvular disease Heart failure	
Hypothyroidism Pericarditis Bradycardia Dilated cardiomyopathy	Obesity Myocardial hypertrophy Heart failure	Small-medium-great vessels vasculitis Myocarditis Vasculitis Coronary artery disease (ectatic/aneurysmatic) Dilated cardiomyopathy Heart failure	
Malignant carcinoid Dilated cardiomyopathy		Inflammatory myopathies Myocarditis Dilated cardiomyopathy Heart failure	
Phaeochromocytoma Supraventricular and ventricular tachycardia Cardiomyopathy Heart failure		Systemic sclerosis (Scleroderma) Myocardial fibrosis Pulmonary hypertension Heart failure (right)	
Acromegaly Dilated cardiomyopathy		Amyloidosis Restrictive cardiomyopathy	
Haemochromatosis Iron overload Dilated cardiomyopathy Heart failure		Sarcoidosis Myocarditis Dilated cardiomyopathy Heart failure	
Anderson-Fabry disease Hypertrophic cardiomyopathy Arrhythmia			

cardiovascular disease risk factors, elevated mean haemoglobin A (1c) and macroalbuminuria were significantly associated with alterations in left ventricular (LV) structure and function.⁸ In overweight and obese women, insulin resistance is associated with increased cardiac remodelling and reduced diastolic function, assessed by CMR.⁹ Finally, osteoprotegerin (OPG) was inversely associated with aortic distensibility, LV volumes and LV diastolic function assessed by CMR, while adipocytokine adiponectin (ADPN) was positively associated with myocardial glucose metabolism (MMRglu) by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography.¹⁰ In another study, CMR was used to assess the effect of rosiglitazone on cardiovascular performance and cardiac function in type 2 diabetes mellitus (T2DM) and proved that rosiglitazone increased peripheral oedema but had no pernicious effects on cardiovascular performance or cardiac function, with modest improvement in selected CMR measures.¹¹ Although insulin and glucose indices are associated with abnormalities in cardiac structure, insulin resistance and worsening glycaemia are consistently and independently associated with left ventricular mass (LVM)/LV end-diastolic volume (LVEDV). These data implicate hyperglycaemia and insulin resistance in concentric LV remodelling.¹²

CMR also documented that few patients with HIV may have a marginally reduced right ventricular ejection fraction (RVEF) but normal right ventricular (RV) dimensions and mass.¹³

Finally, the progression to heart failure in rheumatoid arthritis (RA) may occur through reduced myocardial mass rather than hypertrophy, and both modifiable and non-modifiable factors may contribute to lower levels of left ventricular mass and volume.¹⁴

Myocardial Ischaemia

CMR can detect ischaemia by two different ways:

- Observation of wall motion abnormalities (abnormal wall motion and wall thickening) using the stress factor dobutamine. Compared with stress echocardiogram, stress CMR using dobutamine has better sensitivity (86 % versus 74 %) and specificity (86 % versus 70 %).¹⁵⁻¹⁷
- Observation of myocardial perfusion by the first-pass of a bolus of a T1-shortening contrast agent (first-pass gadolinium) injected into a peripheral vein.^{18,19} Data acquired during intravenous vasodilator-stress (most commonly adenosine) delineate the underperfused

regions associated with myocardial ischaemia. The spatial resolution of CMR myocardial perfusion imaging of 2–3 mm is greatly superior to other imaging modalities, such as nuclear techniques, so that subendocardial ischaemia can be more reliably identified.^{20,21} Recent developments led to further improvements in spatial resolution to around 1 mm in the imaging plane.^{22–24} The interpretation of CMR myocardial perfusion studies in clinical practice have been validated against X-ray angiography, single-photon emission computed tomography (SPECT) and positron emission tomography (PET).^{25,26} Recently, the Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease (CE-MARC) study (the largest, prospective, real-world evaluation of CMR) has established its high diagnostic accuracy in coronary heart disease and superiority over SPECT; therefore it should be adopted more widely than at present for the investigation of coronary heart disease.²⁷

Stress perfusion CMR has already been used for the evaluation of diabetic patients. In T1DM, myocardial perfusion reserve index (MPRI) was independently associated with increased LV torsion.²⁸ In another study, it was documented that young subjects with uncomplicated T1DM have impaired myocardial energetics, irrespective of the duration of diabetes and the impaired cardiac energetics status results from metabolic dysfunction rather than microvascular impairment.²⁹

Finally in a study by our group, adenosine stress CMR, using MPRI evaluation, detected early perfusion changes in asymptomatic T1DM, missed by the usual non-invasive evaluation.³⁰

Stress perfusion CMR has also been applied in multisystem (rheumatic diseases). A 44 % prevalence of abnormal stress myocardial perfusion by CMR in the absence of obstructive CAD was documented in systemic lupus erythematosus (SLE) patients with anginal symptoms. Compared with controls, reduced MPRI was observed in SLE patients and SLE presence was a significant predictor of an abnormal MPRI. These findings are consistent with the hypothesis that anginal chest pain (CP) in SLE patients without obstructive CAD is due to myocardial ischaemia potentially caused by microvascular coronary dysfunction.³¹ Stress myocardial perfusion abnormalities were frequent in RA patients without known cardiac disease. Abnormal CMR perfusion findings were associated with higher RA disease activity, suggesting a role for inflammation in the pathogenesis of myocardial involvement in RA.³² Subclinical myocardial involvement, as detected by stress perfusion CMR, was frequent in asymptomatic patients with systemic sclerosis (SSc).^{33,34} Finally, in sarcoidosis without cardiac symptoms and normal routine assessment, stress perfusion CMR and myocardial inflammation assessment detected early cardiac involvement that may in some cases necessitate immediate treatment.³⁵

Myocardial Viability (Fibrosis Detection or Viability Study) Late Gadolinium Enhanced Imaging

CMR is the most reliable imaging way to detect and quantify scar or fibrotic tissue, due to irreversible myocardial damage (viability study). Following acute ischaemic injury, the myocardial distribution volume of gadolinium is increased due to sarcolemmal rupture and abnormal wash-out kinetics. The preferred imaging time for scar detection is between 10 and 20 minutes after contrast agent administration, when the differences between scar, normal myocardium and blood pool are maximal. This method is referred in the literature as late gadolinium enhanced (LGE) CMR and is the gold standard for the *in*

Figure 1: Anterior Myocardial Scar, Due to Myocardial Infarction, in a Patient with Systemic Lupus Erythematosus

vivo assessment of myocardial scar (see *Figure 1*). CMR can detect infarction in as little as 1 cm³ of tissue, substantially less than other *in vivo* methods, such as echocardiography and nuclear techniques. Furthermore, CMR can detect subendocardial myocardial infarction, missed by SPECT/PET. The CMR extent of scar predicts the potential for functional recovery after revascularisation.^{36–38}

Subendocardial and/or transmural LGE, following the distribution of coronary arteries, are indicative of CAD. However, not only the presence but also the LGE amount plays an important role in patients' prognosis, because even a small area of LGE (<2 % of LV mass) was associated with a greater than seven-fold increase in risk for a major adverse cardiac event.³⁹

CMR can characterise silent scar consistent with myocardial infarction (MI) in diabetic patients without clinical evidence of MI, and has strong association with major adverse cardiovascular events (MACE) and mortality hazards that is incremental to clinical, electrocardiogram (ECG) and LV function combined.⁴⁰

LGE has already been described in vasculitis, myositis, SLE and RA; it may present different patterns including subendocardial or transmural lesions in the territory supplied by the occluded coronary artery, intra-myocardial or subepicardial not following the distribution of coronary arteries, mimicking the pattern of viral myocarditis and/or diffuse subendocardial pattern due to vasculitis.⁴¹

Finally, global subendocardial LGE was identified by CMR in severe cardiac amyloidosis.⁴²

Iron Deposition Assessment

Patients with haemochromatosis are in great risk of iron overload. 'T2-star' (T2*) technique, assessed by CMR, is a non-invasive method for measuring liver and cardiac iron deposition (see *Figure 2*). A significant curvilinear, inverse correlation between iron concentration measured by biopsy and liver T2* was found. Myocardial iron deposition can be reproducibly quantified using T2*. This is the most significant variable for predicting a requirement for targeted treatment of myocardial iron overload and it cannot be replaced by serum ferritin, liver iron or any other measurement. Excellent T2* reproducibility between scanners produced by two different manufacturers supports the feasibility of

Figure 2: T2* Image From a Patient with Iron Deposition, Due to Haemochromatosis

Figure 3: Magnetic Resonance Angiography Shows Subclavian Stenosis in a Patient with Takayasu Disease

widespread implementation of the technique. Myocardial T2* seems to be the most sensitive and easily reproducible index of myocardial iron deposition currently available.⁴³

Therapeutic phlebotomy and iron chelation are the cornerstones of haemochromatosis therapy. The average survival is less than a year in untreated patients with severe cardiac impairment. However, if treated early and aggressively, the survival rate approaches that of the usual population with heart failure. CMR, using T2* measurements, can quantify myocardial iron overload and response to iron reduction therapy by serial imaging evaluation.⁴³

Aortic Stiffness

Aortic distensibility and aortic pulse wave velocity (PWV) are two parameters closely related to the bio-elastic function of the aorta. Quantification of aortic distensibility and PWV by CMR has been shown to be accurate and reproducible and can identify early cardiovascular disease in asymptomatic patients. Gradient echo cine CMR has been applied to assess aortic distensibility and phase-contrast cine CMR to evaluate aortic PWV and to quantify aortic flow.⁴⁴

In type 1 diabetes there are strong adverse effects of hypertension, chronic hyperglycaemia and macroalbuminuria on aortic distensibility.⁴⁵ In another study, a combined CMR assessment of aortic PWV, aortic distensibility and heart function reveals abnormal PWV and distensibility in T2DM that is independent of blood pressure and correlates with

diastolic LV function.⁴⁶ Additionally, aortic elastic function is abnormal in obese subjects without other cardiovascular risk factors.⁴⁷

Finally, juvenile idiopathic arthritis (JIA) is associated with increased aortic stiffness that might suggest subclinical atherosclerosis.⁴⁸

Epicardial Fat

Fat deposits are often found around the heart. This fat can be separated into different compartments. Epicardial fat (EF) is the adipose tissue accumulated between the visceral pericardium and the myocardium, without a structure or fascia separating it from the myocardium and the epicardial vessels. EF has a variable distribution, being more prominent in the atrioventricular and interventricular grooves and right ventricular lateral wall.⁴⁹ Adipocytes' infiltration into the myocardium as well as triglyceride infiltration into myocytes may also occur.

The fat located on the outer surface of the fibrous pericardium differs from EF in their biochemical, molecular and vascular nutrition properties. It is nourished by the pericardiophrenic artery, a branch of the internal thoracic artery,⁴⁹ while EF is nourished by the coronary arteries. The structure that delimitates these layers is the pericardium, seen on imaging tests as a thin layer around the heart, between 1.0 and 4.0 mm, of which visualisation is sometimes difficult.

CMR is considered as the gold standard for the assessment of total body fat and reference modality for the analysis of ventricular volumes and mass, thus making it a natural choice for the detection and quantification of EF.⁵⁰ The total volume of EF can be estimated using the modified Simpson method, in which the epicardial tissue is contoured in each short axis at end of diastole. The interobserver reproducibility of EF volume measurement is superior to the EF thickness measurement (coefficient of variability of 5.9 % for the volumetric method and 13.6 % for EF thickness at the long axis); however, it is technically more difficult.⁵⁰

In prepubertal and early pubertal obese children, EF is a significant marker of increased insulin resistance and associated cardiovascular risk.⁵¹ Additionally, subjects with type 1 diabetes have higher EF than non-diabetic subjects.⁵²

Magnetic Resonance Angiography

Magnetic resonance angiography (MRA) is an imaging modality that comprises various techniques based on two concepts: methods relying on the natural flow effects, the time-of-flight and phase-contrast technique, either in two- or three-dimensional acquisition mode and the more recently developed contrast-enhanced (CE) MRA methods.

A study in diabetic patients, using whole-body magnetic resonance imaging (WB-MRI) and whole-body magnetic resonance angiography (WB-MRA), found a prevalence of 49 % for peripheral artery disease, 25 % for myocardial infarction, 28 % for cerebrovascular disease and 22 % for neuropathic foot. In all vessels, at least 50 % of pathologies were previously unknown. Additionally, myocardial infarction, chronic ischaemic cerebral lesions and atherosclerotic disease were significantly more common in diabetic than in controls.⁵³ MRA has also been applied in the evaluation of great vessels in large vessels vasculitis, such as Takayasu disease (see Figure 3).⁵⁴

Coronary magnetic resonance angiography (CMRA) has already been applied in different systemic diseases. In diabetes mellitus,

Figure 4: Ectatic Right Coronary Artery in a Patient with Microscopic Polyangiitis

CMRA may detect early coronary artery changes.⁵⁵ In patients with systemic antineutrophil cytoplasmic antibodies (ANCA)-related vasculitis, CMRA detected ectatic and/or aneurysmatic coronary arteries (see *Figure 4*).⁵⁶ Additionally, in Kawasaki disease, CMRA is a useful tool for a radiation free serial coronary artery evaluation.⁵⁷ Finally, in HIV patients, CMRA may facilitate the early detection of CAD.⁵⁸

T1 Mapping

CMR has the capability to characterise myocardial tissue using T1 and T2 mapping techniques. Quantitative T1 imaging, in particular, can be used to calculate the myocardial extracellular volume fraction (ECV), a measure of microscopic myocardial remodelling that has been associated with underlying diffuse fibrosis

Diffuse myocardial fibrosis is an underlying contributor to early diabetic cardiomyopathy, as it was documented by the association between myocardial diastolic dysfunction, post-contrast T1 values and metabolic disturbance.⁵⁹ Recently, it was documented that non-contrast T1 mapping had high diagnostic accuracy for detecting cardiac AL amyloidosis, correlated well with markers of systolic and diastolic dysfunction and was potentially more sensitive for detecting early disease than LGE imaging; therefore, elevated myocardial T1 may represent a direct marker of cardiac amyloid load.⁶⁰ In patients with SLE without cardiac symptoms, T1 mapping may detect subclinical myocardial involvement.⁶¹

Myocardial Inflammation

CMR is the ideal technique for the evaluation of inflammatory processes involving the heart. Myocarditis often has a subclinical course, which cannot be easily detected with standard inflammatory indices evaluated in the blood (erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], etc.) and can lead, under special conditions, to dilated cardiomyopathy.⁶² During its early stages it can also remain undetected by the commonly used imaging

Figure 5: Patchy Myocardial Fibrosis, Due to Autoimmune Myocarditis, in a Patient with Hyperthyroidism

techniques (echocardiography or nuclear imaging techniques), because these techniques are unable to distinguish slight tissue structure changes (oedema, cell infiltration), which can occur without associated changes in LVEF, the most often detected parameter by echocardiography. Instead, CMR can perform tissue characterisation, which makes it extremely valuable in myocarditis.

According to current experience, in myocardial inflammation due to infectious causes (i.e. viral myocarditis), a decrease in LVEF was not evident during the course of the disease, while an increase in cardiac troponin was found in only 20 % of cases.²⁰ Additionally, myocardial biopsy is an invasive procedure and according to the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines should be kept only for patients with unexplained new-onset heart failure <2 weeks in duration associated with a normal-sized or dilated left ventricle in addition to haemodynamic compromise, and cannot be used for screening or follow-up tool.⁶² Furthermore its diagnostic value is limited due to a number of reasons (sampling error, variation in observer expertise, etc.).⁶¹

CMR contributes to the diagnosis of myocarditis using three types of images: T2-weighted (T2W), early T1- weighted (T1W) images taken at one minute and delayed enhanced images (LGE) taken 15 minutes after the injection of contrast agent.

T2W is an indicator of tissue water content, which is increased in inflammation or necrosis, such as during myocardial infarction or myocarditis. However, it is not possible to differentiate between necrosis and inflammation only by the use of T2W images. To enhance the detection of pathology on CMR, images after early and delayed gadolinium injection should be obtained. Higher levels of early myocardial enhancement after gadolinium administration are due to increased membrane permeability or capillary blood flow. Membrane permeability is a major contributor as inflammation damages cell membranes through both T-cell perforin and B-cell antibody/complement-mediated processes. The third parameter, which should be also evaluated, is the presence of contrast agent deposition in the delayed images (LGE images) (see *Figure 5*). Myocardial necrosis in the acute phase appears to play a major role in LGE formation, but

also severe oedema could increase the gadolinium distribution and cause delayed enhanced areas. A combined CMR approach using T2W, early and late gadolinium enhancement, has a sensitivity of 76 %, a specificity of 95.5 % and a diagnostic accuracy of 85 % for the detection of myocardial inflammation.^{62,63}

Evaluation of inflammation by CMR has already been applied in pheochromocytoma,⁶⁴ diabetes mellitus,⁶⁵ endocrine² and rheumatic diseases,⁴ and allowed the detection of pathophysiology of cardiac lesions as well as cardiac disease acuity.

Limitations of Cardiac Magnetic Resonance

- Lack of availability;
- high cost;
- high expertise level needed for accurate diagnosis;

- awareness of referring physicians about the applications of the technique; and
- claustrophobia, metallic clips, pacemakers (unless CMR compatible), defibrillators.

Conclusions

CMR, using different sequences, can be of great value for the early and accurate assessment of cardiac involvement due to systemic diseases. CMR is a powerful technique that offers reliable and operator-independent assessment of cardiac anatomy, function, stress perfusion-fibrosis, myocardial-vessel inflammation, aortic distensibility, and iron and fat deposition; additionally it can identify disease acuity. These applications make the technique an excellent tool for heart-vessels assessment, risk stratification and treatment evaluation of patients with systemic diseases. ■

- Dorland's Illustrated Medical Dictionary, 28th edition, Philadelphia, US: W.B. Saunders Co; A Division of Harcourt Brace & Company, 1994;489,1653.
- Mavrogeni S, Markussis V, Bratis K, et al., Hyperthyroidism induced autoimmune myocarditis. Evaluation by cardiovascular magnetic resonance and endomyocardial biopsy, *Int J Cardiol*, 2012;158(1):166–8.
- Roman-Campos D, Cruz JS, Current aspects of thiamine deficiency on heart function, *Life Sci*, 2014;98(1):1–5.
- Mavrogeni S, Sfrikakis PP, Gialafos E, et al., Cardiac tissue characterization and the diagnostic value of cardiovascular magnetic resonance in systemic connective tissue diseases, *Arthritis Care Res (Hoboken)*, 2014;66(1):104–12.
- Hemkens LG, Bucher HC, HIV infection and cardiovascular disease, *Eur Heart J*, 2014;35(21):1373–81.
- Schalla S, Nagel E, Lehmkuhl H, et al., Comparison of magnetic resonance real-time imaging of LV function with conventional magnetic resonance imaging and echocardiography, *Am J Cardiol*, 2001;87:5–99.
- Bottini PB, Carr AA, Prisant M, et al., Magnetic resonance imaging compared to echo/phy to assess LV MASS in the hypertensive patient, *Am J Hypertens*, 1995;8:221–6.
- Turkbey EB, Backlund JY, Genuth S, et al., Myocardial structure, function and scar in patients with type 1 diabetes mellitus, *Circulation*, 2011;124(16):1737–46.
- Utz W, Engeli S, Haufe S, et al., Myocardial steatosis, cardiac remodelling and fitness in insulin-sensitive and insulin-resistant obese women, *Heart*, 2011;97(19):1585–9.
- Chen WJ, Rijzewijk LJ, van der Meer RW, et al., Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men, *Cardiovasc Diabetol*, 2011;10:67.
- McGuire DK, Abdullah SM, See R, et al., Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function, *Eur Heart J*, 2010;31:2262–70.
- Velagaleti RS, Gona P, Chuang ML, et al., Relations of insulin resistance and glycemic abnormalities to cardiovascular magnetic resonance measures of cardiac structure and function: the Framingham Heart Study, *Circ Cardiovasc Imaging*, 2010;3(3):257–63.
- Kjaer A, Lebech AM, Gerstoft J, et al., Right ventricular volume and mass determined by cine magnetic resonance imaging in HIV patients with possible right ventricular dysfunction, *Angiology*, 2006;57(3):341–6.
- Giles JT, Malayeri AA, Fernandes V, et al., Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging, *Arthritis Rheum*, 2010;62(4):940–51.
- Nagel E, Lehmkuhl HB, Bocksch W, et al., Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography, *Circulation*, 1999;99:763–70.
- Wahl A, Paetsch I, Roethemeyer S, et al., High-dose dobutamine-atropine stress cardiovascular magnetic resonance for follow-up after coronary revascularization procedures in patients with wall motion abnormalities at rest, *Radiology*, 2004;233:210–6.
- Hundley WG, Hamilton CA, Thomas MS, et al., Utility of fast cine magnetic resonance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography, *Circulation*, 1999;100:1697–702.
- Danias PG, Gadolinium-enhanced cardiac magnetic resonance imaging: expanding the spectrum of clinical applications, *Am J Med*, 2001;110:591–2.
- Schwittler J, Myocardial perfusion imaging by cardiac magnetic resonance, *J Nucl Cardiol*, 2006;13:841–54.
- Schwittler J, Nanz D, Kneifel S, et al., Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography, *Circulation*, 2001;103:2230–5.
- Plein S, Ryf S, Schwittler J, et al., Dynamic contrast-enhanced myocardial perfusion MRI accelerated with k-t sense, *Magn Reson Med*, 2007;58:777–85.
- Gebker R, Jahnke C, Paetsch I, et al., Diagnostic performance of myocardial perfusion MR at 3 T in patients with coronary artery disease, *Radiology*, 2008;247:57–63.
- Cheng AS, Pegg TJ, Karamitsos TD, et al., Cardiovascular magnetic resonance perfusion imaging at 3-tesla for the detection of coronary artery disease: a comparison with 1.5-tesla, *J Am Coll Cardiol*, 2007;49:2440–9.
- Fritz-Hansen T, Hove JD, Kofoed KF, et al., Quantification of MRI measured myocardial perfusion reserve in healthy humans: a comparison with positron emission tomography, *J Magn Reson Imaging*, 2008;27:818–24.
- Al-Saadi N, Nagel E, Gross M, et al., Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance, *Circulation*, 2000;101:1379–83.
- Schwittler J, Wacker CM, van Rossum AC, et al., MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial, *Eur Heart J*, 2008;29(4):480–9.
- Greenwood JP, Maredia N, Younger JF, et al., Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial, *Lancet*, 2012;379(9814):453–60.
- Shivu GN, Abozguia K, Phan TT, et al., Increased left ventricular torsion in uncomplicated type 1 diabetic patients: the role of coronary microvascular function, *Diabetes Care*, 2009;32(9):1710–2.
- Shivu GN, Phan TT, Abozguia K, et al., Relationship between coronary microvascular dysfunction and cardiac energetics impairment in type 1 diabetes mellitus, *Circulation*, 2010;121(10):1209–15.
- Mavrogeni S, Bratis K, Gavra P, et al., Stress cardiac magnetic resonance reveals myocardial perfusion impairment in asymptomatic diabetes mellitus type I, missed by the routine non-invasive evaluation, *Int J Cardiol*, 2013;167(6):e167–9.
- Ishimori ML, Martin R, Berman DS, et al., Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus, *JACC Cardiovasc Imaging*, 2011;4(1):27–33.
- Kobayashi Y, Giles JT, Hirano M, et al., Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study, *Arthritis Res Ther*, 2010;12(5):R171.
- Kobayashi H, Yokoe I, Hirano M, et al., Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis, *J Rheumatol*, 2009;36(1):106–12.
- Mavrogeni S, Bratis K, van Wijk K, et al., Myocardial perfusion-fibrosis pattern in systemic sclerosis assessed by cardiac magnetic resonance, *Int J Cardiol*, 2012;159(3):e56–8.
- Mavrogeni S, Kouranos V, Sfrikakis PP, et al., Myocardial stress perfusion-fibrosis imaging pattern in sarcoidosis, assessed by cardiovascular magnetic resonance imaging, *Int J Cardiol*, 2014;172(2):501–3.
- Klein C, Nekolla SG, Bengel FM, et al., Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography, *Circulation*, 2002;105:162–7.
- Wagner A, Mahrholdt H, Holly TA, et al., Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study, *Lancet*, 2003;361:374–9.
- Bondarenko O, Beek AM, Nijveldt R, et al., Functional outcome after revascularization in patients with chronic ischemic heart disease: a quantitative late gadolinium enhancement CMR study evaluating transmural scar extent, wall thickness and periprocedural necrosis, *J Cardiovasc Magn Reson*, 2007;9:815–21.
- Kwong RY, Chan AK, Brown KA, et al., Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease, *Circulation*, 2006;113:2733–43.
- Kwong RY, Sattar H, Wu H, et al., Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction, *Circulation*, 2008;118(10):1011–20.
- Mavrogeni S, Sfrikakis P, Dimitroulas T, et al., Edema and fibrosis imaging by cardiovascular magnetic resonance: How can the experience of Cardiology be best utilized in rheumatological practice?, *Semin Arthritis Rheum*, 2014; pii: S0049-0172(14)00006-7.
- Mori M, Kitagawa T, Sasaki Y, et al., Global subendocardial late gadolinium enhancement on cardiac magnetic resonance imaging in severe cardiac AL amyloidosis, *Int J Hematol*, 2013;97(2):159–60.
- Gulati V, Harikrishnan P, Palaniswamy C, et al., Cardiac involvement in hemochromatosis, *Cardiol Rev*, 2014;22:56–68.
- Voges I, Jerosch-Herold M, Hedderich J, et al., Normal values of aortic dimensions, distensibility, and pulse wave velocity in children and young adults: a cross-sectional study, *J Cardiovasc Magn Reson*, 2012;14:77.
- Turkbey EB, Redheuil A, Backlund JY, et al., Aortic distensibility in type 1 diabetes, *Diabetes Care*, 2013;36(8):2380–7.
- van der Meer RW1, Diamant M, Westenberg JJ, et al., Magnetic resonance assessment of aortic pulse wave velocity, aortic distensibility, and cardiac function in uncomplicated type 2 diabetes mellitus, *J Cardiovasc Magn Reson*, 2007;9(4):645–51.
- Robinson MR, Scheuermann-Freestone M, Leeson P, et al., Uncomplicated obesity is associated with abnormal aortic function assessed by cardiovascular magnetic resonance, *J Cardiovasc Magn Reson*, 2008;10:10.
- Argyropoulou MI, Kiortsis DN, Daskas N, et al., Distensibility and pulse wave velocity of the thoracic aorta in patients with juvenile idiopathic arthritis: an MRI study, *Clin Exp Rheumatol*, 2003;21(6):794–7.
- Kim HM, Kim KJ, Lee HJ, et al., Epicardial adipose tissue thickness is an indicator for coronary artery stenosis in asymptomatic type 2 diabetic patients: its assessment by cardiac magnetic resonance, *Cardiovasc Diabetol*, 2012;11:83.
- Iacobellis G, Ribaudo MC, Assael F, et al., Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk, *J Clin Endocrinol Metab*, 2003;88(11):5163–8.
- Manco M, Morandi A, Marigliano M, et al., Epicardial fat, abdominal adiposity and insulin resistance in obese pre-pubertal and early pubertal children, *Atherosclerosis*, 2013;226(2):490–5.
- Iacobellis G, Diaz S, Mendez A, Goldberg R, Increased epicardial fat and plasma leptin in type 1 diabetes independently of obesity, *Nutr Metab Cardiovasc Dis*, 2014;24(7):725–9.
- Weckbach S, Findelsen HM, Schoenberg SO, et al., Systemic cardiovascular complications in patients with long-standing diabetes mellitus: comprehensive assessment with whole-body magnetic resonance imaging/magnetic resonance angiography, *Invest Radiol*, 2009;44(4):242–50.
- Mavrogeni S, Dimitroulas T, Chatziioannou SN, Kitis G, The role of multimodality imaging in the evaluation of Takayasu arteritis, *Semin Arthritis Rheum*, 2013;42(4):401–12.
- Abd-Elmoniem KZ, Garib AB, Pettigrew RI, Coronary vessel wall 3-T MR imaging with time-resolved acquisition of

- phase-sensitive dual inversion-recovery (TRAPD) technique: initial results in patients with risk factors for coronary artery disease, *Radiology*, 2012;265(3):715–23.
56. Mavrogeni S, Manoussakis MN, Karagiorga TC, et al., Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides, *Arthritis Rheum*, 2009;61(8):1121–9.
 57. Mavrogeni S, Papadopoulos G, Douskou M, et al., Magnetic resonance angiography, function and viability evaluation in patients with Kawasaki disease, *J Cardiovasc Magn Reson*, 2006;8(3):493–8.
 58. Gharib AM1, Abd-Elmoniem KZ, Pettigrew RI, Hadigan C, Noninvasive coronary imaging for atherosclerosis in human immunodeficiency virus infection, *Curr Probl Diagn Radiol*, 2011;40(6):262–7.
 59. Jellis C, Wright J, Kennedy D, et al., Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy, *Circ Cardiovasc Imaging*, 2011;4(6):693–702.
 60. Karamitsos TD, Piechnik SK, Banyersad SM, et al., Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis, *JACC Cardiovasc Imaging*, 2013;6(4):488–97.
 61. Puntmann VO, D'Cruz D, Smith Z, et al., Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus, *Circ Cardiovasc Imaging*, 2013;6(2):295–301.
 62. Dennert R, Crijns HJ, Heymans S, Acute viral myocarditis, *Eur Heart J*, 2008;29:2073–82.
 63. Friedrich MG, Sechtem U, Schulz-Menger J, et al., Cardiovascular magnetic resonance in myocarditis: A JACC White Paper, *J Am Coll Cardiol*, 2009;53(17):1475–87.
 64. Ferreira V, Marcelino M, Piechnik S, et al., 122 Cardiac Abnormalities are Common in Patients Diagnosed with Pheochromocytoma as Detected by Cardiovascular Magnetic Resonance Imaging, *Heart*, 2014;100 Suppl 3:A70.
 65. Makino K, Nishimae I, Suzuki N, et al., Myocarditis with fulminant type 1 diabetes mellitus diagnosed by cardiovascular magnetic resonance imaging: a case report, *BMC Res Notes*, 2013;6:347.